Education
About Us
Working with TipRanks
Follow Us
TCAL - AI Analysis
Top Page
T. Rowe Price Capital Appreciation Premium Income ETF (TCAL)
Rating:72Outperform
Price Target:
$28.00
Positive Factors
Strong Top Holdings
Several key holdings, such as Kroger, Visa, and Abbott Laboratories, have delivered strong year-to-date performance, supporting the fund’s overall returns.
Sector Diversification
The ETF is spread across multiple sectors, including Health Care, Utilities, and Financials, reducing reliance on any single industry.
Reasonable Expense Ratio
The fund’s expense ratio is relatively low, making it cost-effective compared to many actively managed ETFs.
Negative Factors
Underperforming Holdings
Some top holdings, such as SBA Communications and Arthur J Gallagher & Co, have lagged in year-to-date performance, dragging on the fund’s momentum.
Geographic Over-Concentration
The ETF is entirely focused on U.S. companies, which limits exposure to international markets and diversification.
Mixed Recent Performance
The fund has shown weak year-to-date returns despite a positive one-month rebound, indicating inconsistent performance.
TCAL vs. SPDR S&P 500 ETF (SPY)
AUM168.61M
RegionNorth America
Expense Ratio0.34%
Beta0.32
IssuerT. Rowe Price
Inception DateMar 26, 2025
Dividend Yield6.49%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume173,362
30 Day Avg. Volume112,986
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
27.24Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering73
TCAL Summary
The T. Rowe Price Capital Appreciation Premium Income ETF (TCAL) is an actively managed fund that invests in a wide range of U.S. companies across sectors like healthcare, utilities, and financials. It uses a covered call strategy to generate income while aiming for steady growth and reduced volatility. Some of its top holdings include well-known companies like Thermo Fisher and PepsiCo. This ETF could be a good choice for investors seeking a balanced approach to income and growth. However, new investors should be aware that the fund’s performance can fluctuate with the overall market, as it is broadly diversified across many sectors.
How much will it cost me?The T. Rowe Price Capital Appreciation Premium Income ETF (TCAL) has an expense ratio of 0.34%, meaning you’ll pay $3.40 per year for every $1,000 invested. This is higher than the average for passively managed ETFs because TCAL is actively managed, using strategies like covered call options to enhance income and manage risk.
What would affect this ETF?Positive drivers for TCAL could include stable or declining interest rates, which may support growth in sectors like health care and technology, as well as strong consumer demand benefiting defensive stocks like PepsiCo and Kroger. On the negative side, rising interest rates or economic slowdowns could pressure financial and industrial sectors, while regulatory changes in health care or real estate could impact top holdings like Thermo Fisher and SBA Communications. TCAL’s covered call strategy may help mitigate volatility in uncertain market conditions.
TCAL Top 10 Holdings
The T. Rowe Price Capital Appreciation Premium Income ETF (TCAL) leans heavily on health care and utilities, with notable contributions from names like Thermo Fisher and PepsiCo, both showing steady growth and operational strength. However, real estate holdings such as SBA Communications and American Tower are lagging, weighed down by valuation concerns and external challenges. Kroger has been a bright spot, benefiting from e-commerce growth, while Visa’s performance has been mixed despite strong fundamentals. With a focus on U.S. stocks, TCAL’s sector concentration in health care and utilities offers stability, but some holdings may temper overall momentum.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Visa | 2.34% | $3.89M | $649.07B | 15.44% | 75 Outperform | |
| Thermo Fisher | 2.29% | $3.80M | $212.23B | 1.69% | 73 Outperform | |
| S&P Global | 2.25% | $3.74M | $150.50B | 2.32% | 73 Outperform | |
| Mastercard | 2.24% | $3.72M | $488.57B | 7.61% | 69 Neutral | |
| Linde | 2.24% | $3.72M | $192.47B | -10.07% | 66 Neutral | |
| Service International | 2.16% | $3.58M | $11.41B | -0.90% | 71 Outperform | |
| American Tower | 2.15% | $3.57M | $82.69B | -16.72% | 65 Neutral | |
| Abbott Laboratories | 2.06% | $3.42M | $215.34B | 5.26% | 77 Outperform | |
| Gilead Sciences | 2.01% | $3.33M | $151.44B | 35.85% | 75 Outperform | |
| Arthur J Gallagher & Co | 2.00% | $3.33M | $62.30B | -13.73% | 69 Neutral |
TCAL Technical Analysis
Negative
―
Price Trends
24.03
Negative
23.95
Negative
Market Momentum
-0.06
Positive
37.85
Neutral
9.41
Positive
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For TCAL, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 24.13, equal to the 50-day MA of 24.03, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of -0.06 indicates Positive momentum. The RSI at 37.85 is Neutral, neither overbought nor oversold. The STOCH value of 9.41 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TCAL.
TCAL Peer Comparison
Comparison Results
Performance Comparison
TCAL
T. Rowe Price Capital Appreciation Premium Income ETF
23.63
0.11
0.47%
SYLD
Cambria Shareholder Yield ETF
―
―
―
PLDR
Putnam Sustainable Leaders ETF
―
―
―
ABFL
Fcf Us Quality Etf
―
―
―
BGDV
Bahl & Gaynor Dividend ETF
―
―
―
EBI
Longview Advantage ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents